Legal Status Overview
Gray AreaDelaware has no statute, administrative regulation, or Board of Pharmacy rule that names 'peptides' or 'research chemicals' as a distinct legal category, so the status of compounds like BPC-157, TB-500, and compounded semaglutide/tirzepatide in Delaware is determined almost entirely by federal FDA law layered on top of Delaware's general pharmacy, compounding, and controlled-substance statutes. Peptides that are FDA-approved drugs can be prescribed and dispensed normally in Delaware; unapproved peptides sold as 'research use only' chemicals sit in a gray zone where Delaware law does not speak directly, but federal law generally treats them as unapproved new drugs. Delaware licensees who compound must follow USP 795/797 (and USP 800) standards and remain subject to Board discipline, and out-of-state pharmacies and 503B outsourcing facilities shipping into Delaware need a Delaware permit. As of this research date, no Delaware-specific peptide bill, Board bulletin, or attorney general guidance targeting peptides was located.
Key Points
- Searches of the Delaware Code, the Delaware Administrative Code (Board of Pharmacy Reg. 2500), the Delaware Register of Regulations, and Delaware General Assembly bill tracking surfaced no Delaware provision that names peptides, 'research chemicals,' or research-use-only compounds as a distinct regulated category; this negative finding reflects the absence of a located source rather than a source affirmatively stating there is no such law. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- Delaware regulates peptide preparation through general compounding rules: 24 DE Admin Code 2500-10.0 requires all individuals and entities licensed by the Delaware Board of Pharmacy who engage in compounding to comply with the current editions of USP Chapters 795 and 797, and to be in compliance with (or have an approved plan for) USP 800. [1]
- Delaware's pharmacy statute defines 'compounding' at 24 Del. C. § 2502 to include preparation of a drug on a practitioner's prescription or initiative, or incident to research, teaching, or chemical analysis and not for sale or dispensing, and states that all compounding must comply with applicable USP standards. [2]
- Delaware's current compounding regulation (Reg. 10.0) was rewritten by the Board of Pharmacy to establish comprehensive non-sterile and sterile compounding requirements aligned with USP Chapters 795 and 797, rather than to address any specific drug class such as peptides. [3]
- A facility registered with the FDA as an outsourcing facility under Section 503B of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353b) that does business within or into Delaware falls under the Delaware Board of Pharmacy's permit requirements in 24 DE Admin Code 2500-8.0, which is how federal 503B status is imported into Delaware licensing law. [4]
- Any pharmacy located outside Delaware that delivers a prescription drug to a Delaware patient is a 'nonresident pharmacy' that must obtain a Delaware permit, and the Board may suspend or revoke that permit if the pharmacy violates federal law or another state's law — the main hook Delaware has over out-of-state peptide and compounded-GLP-1 shippers. [5]
- Delaware's Uniform Controlled Substances Act contains a definitional quirk relevant to hormone-type products, providing at 16 Del. C. § 4701 that 'human growth hormone' is synonymous with 'human chorionic gonadotropin,' while anabolic steroids are defined by reference to § 4718(f); research peptides such as BPC-157 and TB-500 are not listed as scheduled substances there. [6]
- The binding constraint on compounded GLP-1 peptides in Delaware is federal, not state: FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025 with phased enforcement deadlines requiring compounders to wind down, and has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. [7]
- The Delaware Board of Pharmacy's most recent compounding-related rulemaking activity (proposed 2024, re-noticed for a February 2025 hearing) amended the compounding subsection 5.1.6 and added sections on pharmacist work conditions and declining to fill prescriptions, with no peptide-specific provision appearing in the notice. [8]
Sources
Last researched: 2026-08-10